Updated: Oct 19
Medically reviewed by ChinaCureLink Team
Table of Content
Why This Case Matters
This case follows Mr. Kemal Aydin (alias), an 80-year-old retired physician from Turkey with severe, treatment-resistant COPD, who traveled to a hospital within Hainan's Boao Lecheng Pilot Zone for a combined regenerative procedure and ensifentrine — a next-generation COPD drug not otherwise available in China.
For international patients with severe COPD who've exhausted standard medication options at home, ChinaCureLink can help evaluate access to this same combined treatment approach.
Key Takeaways |
|
Patient Background
Mr. Aydin spent decades practicing as a general physician, having trained at the University of Ankara School of Medicine, studied neurosurgery in the Netherlands, and later lived and worked in the United States. A long smoking history caught up with him in the form of severe COPD, eventually reaching GOLD stage 4 — the most advanced classification. Standard COPD medications at multiple hospitals in Turkey and the UK brought little improvement. His quality of life declined sharply: walking just 20 meters could trigger severe breathlessness, nighttime coughing became frequent, and everyday activities grew increasingly restricted.
The Care Team and Approach
Drawing on his own medical background, Mr. Aydin and his team had a habit of tracking cutting-edge respiratory literature, which is how he learned about a hospital within Hainan's Boao Lecheng Pilot Zone and the international reputation of its respiratory specialists. Accompanied by his wife, he traveled to China in search of a treatment plan standard care hadn't been able to offer him.
Professor Lin Zhihua (pseudonym) led the initial evaluation of Mr. Aydin's complex case, assessing his condition, physical tolerance, and suitability for advanced treatment. Professor Han Yumei (pseudonym), alongside the hospital's anesthesia team, then worked to ensure the safety and feasibility of the procedure being considered. On June 26, Mr. Aydin was formally admitted, and the care team completed a full set of pulmonary function tests, airway inflammation assessment, and comprehensive cardiac and pulmonary screening to fully understand his current condition.
On July 1, the medical team performed an advanced regenerative lung procedure. Once his recovery from that procedure was underway, the team added ensifentrine — delivered via a standard jet nebulizer — along with structured nebulized therapy and rehabilitation training, forming a combined, multi-pronged treatment plan tailored to his severe presentation.
Treatment Timeline/ Process
Before Treatment (Turkey and the UK)
Decades of smoking led to severe COPD, eventually reaching GOLD stage 4
Treated with standard COPD medications at multiple hospitals, with little meaningful improvement
Quality of life severely restricted, with breathlessness triggered by walking just 20 meters
At the Hospital (China)
June 26: Formally admitted; underwent full pulmonary function testing, airway inflammation assessment, and cardiac/pulmonary screening
July 1: Underwent an advanced regenerative lung procedure
Began treatment with ensifentrine, combined with nebulized therapy and rehabilitation training
Respiratory condition improved steadily over the following days
July 2: Discharged from the hospital
Outcome
Mr. Aydin's respiratory condition improved steadily as the combined treatment plan took effect, and he was discharged just a day after starting the multi-pronged regimen. As a physician himself, he specifically noted how professional and standardized the treatment process felt, saying it matched his own expectations for evidence-based care. His individual case aside, ensifentrine's broader clinical trial data has shown clinically meaningful improvements in lung function and quality of life for COPD patients regardless of disease severity — though, as with any treatment, individual results vary.
How ChinaCureLink Can Help International Patients to Access This Treatment
Severe, treatment-resistant COPD often leaves patients with few remaining options once standard medications have been tried without success. Mr. Aydin's case shows what's possible when regenerative treatment and next-generation medication are combined at a hospital equipped to offer both. ChinaCureLink helps international COPD patients get a specialized case review and connects them with hospitals in China offering this combination approach, coordinating medical record translation, hospital matching, and every logistical step from first inquiry through treatment and follow-up.
Get a Second Opinion Before Fly to China
For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
★★★★☆ Sarah Zhang · Canada· Jul 2024 · Verified “The interpreter during the video call was fantastic — super professional and answered all our questions clearly and quickly. The professor was also very patient and gave us detailed and honest guidance on our treatment options.” |
★★★★★ Andrew Goh · Singapore · Aug 2024 · Verified “My first contact with Medebound was over a year ago. Jason has always been responsive, even when I wasn't ready to proceed. When I finally did, the consultation was seamlessly arranged and the specialist was outstanding.” |
★★★★★ Daniel Wong · Singapore · Aug 2024 · Verified “I have dry eye and nothing seemed to be working, even with different medications. I heard about a medication from the U.S. that’s supposed to be really effective, but I didn’t want to try it without talking to a doctor first. MEDEBOUND connected me with a top ophthalmologist in the U.S. and it was so reassuring to get their expert advice.” |
★★★★☆ Pongsakorn · Thailand · Feb 2025 · Verified “Kiki at Medebound is amazing — so professional and helpful! They got my video consultation with an MD Anderson expert set up super fast, within just 5 working days. I am so grateful for their support.” |
Frequently Asked Questions
Is ensifentrine available for COPD treatment in China?
Ensifentrine is not broadly approved in mainland China, but it's accessible through Hainan's Boao Lecheng Pilot Zone under a special early-access regulatory pathway, at hospitals approved to administer it.
What treatment options exist for severe (stage 4) COPD when standard medications haven't helped?
Options can include next-generation medications like ensifentrine, combined with regenerative procedures and structured pulmonary rehabilitation. A specialist evaluation is needed to determine what combination is appropriate for a given case.
How can international patients access this combined COPD treatment approach in China?
Access typically starts with a case review, where medical records, pulmonary function history, and imaging are submitted for evaluation. ChinaCureLink coordinates this process and helps match patients with hospitals experienced in advanced COPD treatment.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
Disclaimer
This account reflects one patient's individual experience, which will vary by case, diagnosis stage, and other clinical factors. ChinaCureLink facilitates access to hospitals and treatment coordination — we do not provide medical care ourselves, and this content is not medical advice. Patients and families should consult a qualified pulmonologist before making treatment decisions.
